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 The pathogenic yeast Candida glabrata is the second-most common cause of 
candidiasis in humans after Candida albicans. Interestingly, C. glabrata is 
phylogenetically closer to Saccharomyces cerevisiae than C. albicans.  One important 
virulence factor in C. glabrata is its inherent resistance to the azole class of antifungals, 
necessitating the continued discovery of novel antifungal agents.  Many antifungals target 
ergosterol or ergosterol biosynthesis.  In an attempt to look for new potential drug targets 
in C. glabrata, homologues of the genes in S. cerevisiae that regulate the transcription of 
phospholipid biosythesis (the inositol regulon) were examined.  The S. cerevisiae inositol 
regulon consists of a heterodimeric transcriptional activator encoded by the genes INO2 
and INO4 and a repressor encoded by OPI1, none of which are essential.  The most well 
studied target of these genes is INO1, whose protein product converts glucose-6-
phosphate to inositol-1-phosphate for the synthesis of phosphatidylinositol in the absence 
of inositol. Disruption of INO2 or INO4 blocks transcription of several phospholipid 
biosynthetic genes including INO1, resulting in inositol auxotrophy. Disruption of OPI1 
causes overproduction of INO1 and other genes. Surprisingly, it was found that CgOPI1 
is essential for viability in C. glabrata.  This was found to be true for strains in both the 
BG2 and ATCC2001 backgrounds indicating that this is not just a strain-specific effect. 
This is very different from S. cerevisiae, where the Scopi1∆ mutant grows robustly. 
 These results led to the hypothesis that the CgOPI1 gene is necessary for viability 
because it causes overexpression of a target of the inositol regulon transcriptional 




 Disruption of CgINO2 or CgINO4 leads inositol auxotrophy due to the inability to 
transcribe regulon targets such as CgINO1.  The Cgopi1∆ mutant’s viability defect can be 
rescued by disruption of the Cgino2∆ gene.  The Cgopi1∆ Cgino2∆ double mutant is 
viable in the absence of CgOPI1 on a plasmid.  These results indicate that blocking the 
expression of a gene that is activated by the inositol regulon can rescue the Cgopi1∆ 
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Background and Introduction 
Background of Candida glabrata and Candida spp. 
 
 The Candida genus consists of a heterogeneous group of about 200 yeast species.  
Some Candida species are the causative agents of candidiasis, a disease with a wide 
clinical spectrum that includes superficial infections of the oral and vaginal cavities as 
well as systemic infections.  Candidiasis in the form of oral thrush was first documented 
as far back as the fourth century B.C. by Hippocrates and again in 1665 by the London 
journalist, Samuel Pepys.  The initial discovery of the thrush organism is credited to 
Langenbeck in 1839 who mistook it for the causative agent of typhoid fever.  This 
organism eventually was recognized as a fungus and came to be known as Monilia 
albicans before receiving its current connotation of Candida albicans [1-3].   
Despite the size of the Candida genus, relatively few of its known species are of 
any medical significance, and in the early twentieth century, only Candida albicans was 
thought to be of clinical importance.  It was not until the latter part of the twentieth 
century that there was an increase in the isolation of previously nonpathogenic species 
from sites of infection [2].  This accompanied a general rise in nosocomial candidiasis, 
which was due to an increasing population of immunocompromised patients.  The 
contributing factors to this include growing numbers of patients hospitalized for acquired 
immunodeficiency syndrome (AIDS) as well as medical advances such as intravenous 
catheters and chemotherapeutic treatments, which allow longer survival for people with 




Also, the incidence of oral colonization well as the proportion of blood stream infections 
caused by some non-albicans species such as C. glabrata increases with age [5, 6].    
Candida species have become the most important cause of opportunistic mycoses 
worldwide and currently rank fourth among causes of nosocomial bloodstream infections 
[5].  Although historically considered nonpathogenic, Candida glabrata is increasingly 
isolated in both bloodstream and mucosal infections.  It is now commonly cited as second 
only to C. albicans in causing both oral and invasive candidiasis and has been associated 
with high mortality despite indications of low virulence [5-7].  Although C. albicans 
currently is not being challenged for its position as the primary cause of invasive 
candidiasis, the percentage of C. albicans isolates appears to be decreasing and is 
accompanied by a rise in non-albicans species [5].   
Candida glabrata was originally classified in the genus Torulopsis.  The 
distinguishing factor between the two genera was the ability of Candida to display hyphal 
or pseudohyphal growth and the inability of Torulopsis to do so.  It was proposed that the 
two genera be merged in 1978, and this remained a controversy for several years before it 
was finally shown in 1997 that the basis of this separation was inadequate [8]. Although 
most species in the genus Candida do exist in both yeast and hyphal forms, C. glabrata 
has not been demonstrated to form hyphae.  It was eventually shown that C. glabrata 
could undergo a morphological change by exhibiting pseudohyphal growth during 
nitrogen starvation [9]. 
The genus Candida belongs to the Ascomycetes class of fungi.  Several species 




the genus were considered to be asexual, including the pathogenic yeast, Candida 
albicans [10].  In 1999 it was discovered that C. albicans contained a mating type-like 
(MTL) locus, which is similar to the MAT locus of Saccharomyces cerevisiae [11].   
Further study revealed that several genes involved in mating in S. cerevisiae have 
orthologues in C. albicans [12].  Mating was eventually described for C. albicans 
between strains of opposite mating types that had undergone a phenotypic switch from 
white to opaque [13].  A sexual cycle has never been described in C. glabrata, but it does 
have conserved sexual genes, including at least 31 homologues of genes that function in 
meiosis in S. cerevisiae.  Among these genes are those for α-factor as well as a putative 
MTL locus; however, it lacks some genes that are necessary for mating including STE2 
and STE3, to which α-factor and a-factor bind, and MFA1, which is need to make a-
factor.  C. glabrata has two silent mating loci, MTL1 and MTL2, similar to HMR and 
HML in S. cerevisiae, but similar loci appear to be absent from C. albicans [14].  C. 
glabrata also undergoes phenotypic switching, and since this has been shown to be 
necessary for C. albicans mating, there could potentially be a cryptic sexual cycle yet to 
be elucidated in C. glabrata [13].  Interestingly, in yeasts that do have teleomorphic 
forms, the asexual form is the one that is isolated from sites of infection, suggesting that 
mating may be disadvantageous in pathogenicity [14].    
Despite the clinical similarities between C. albicans and C. glabrata, the two 
organisms are quite different phylogenetically, with haploid C. glabrata actually being 
more closely related to Saccharomyces cerevisiae (Figure A.1).  Orthologous proteins in 




G+C content of C. glabrata is similar to the 38.3% of S. cerevisiae [15].  This same 
conclusion was drawn based on the homology of the 18S rRNA sequence [16].  C. 
albicans along with various Candida species also have a genetic code alteration in which 
they translate CTG codons as serine rather than leucine, but C. glabrata lacks this 
reassignment of codon usage [17].  Another difference between the two species is the 
inability of C. glabrata to assimilate any sugars other than glucose and trehalose, which 
accompanies its high numbers of gene loss including those genes involved in the 
metabolism of galactose, phosphate, nitrogen, and sulfur [10, 18]. 
Virulence Factors 
 
  C. albicans and C. glabrata differ in their known virulence factors, and C. 
glabrata lacks several of the virulence factors that had been identified in C. albicans such 
as the production of secreted proteases.  Another virulence factor that C. albicans 
possesses and C. glabrata lacks is its ability to undergo filamentation.  These 
morphological changes increase adherence and tissue invasion, and C. albicans can form 
both pseudohyphae and hyphae, whereas there is no clinical evidence that C. glabrata 
exhibits a change in morphology between the commensal and pathogenic forms, although 
it does form pseudohyphae in vitro [7, 15].     
The virulence factors C. glabrata does have include cell-associated proteases and 
adhesins.  The C. glabrata family of adhesions is discussed first.  A mutant screen 
revealed that deletion of the gene EPA1, or epithelial adhesion 1, significantly reduced 
the adhesion of C. glabrata to human epithelial cells [19].  It has since been shown that 




and at least two others of these, EPA6 and EPA7, are able to mediate adherence; 
however, they are normally kept silent via subtelomeric silencing mediated by the RIF1 
and SIR3 genes [20].  The silencing of the SIR genes and subsequent induction of EPA6 
and EPA7 occurs as a result of the limitation of nicotinic acid (NA), for which C. 
glabrata is an auxotroph.  Because urine is NA-limiting, the EPA6 and EPA7 genes are 
transcribed during urinary tract infections, and their expression in this environment may 
also contribute to the colonization of catheters by C. glabrata [21].  
The other potential virulence factor for C. glabrata is a family of GPI-linked 
aspartyl proteases.  These genes were called YPS because of their homology to a group of 
genes by the same name in S. cerevisiae.  In S. cerevisiae the YPS genes are involved in 
cell wall remodeling, and a similar function is suspected in C. glabrata.  They are 
required for in vitro survival of C. glabrata during stationary phase or conditions of cell 
wall stress.  In addition, the C. glabrata YPS genes were shown to be necessary for 
survival within macrophages, and this family of genes was identified because of its 
upregulation upon internalization of C. glabrata by macrophages [22].  C. glabrata 
proteases differ from those of other pathogenic Candida species in that they are not 
secreted extracellularly.  C. albicans has a family of secreted aspartyl proteases (SAP) 
which are encoded by the genes SAP1-10.  Several studies have correlated production of 
these proteases with virulence in C. albicans.  Although different from the YPS proteases 
in C. glabrata, the SAP family does contain two genes, SAP 9 and SAP10 that encode 




Phospholipases could play a role in C. glabrata infections as well because of their 
potential to compromise host cell membranes.  Evidence for this mechanism of action has 
been given in both fungal and non-fungal pathogens, including C. albicans.  
Phospholipase activity was detected in several other Candida species; however, there was 
significantly less production in non-albicans species compared to C. albicans.  
Nevertheless, phospholipase B was secreted by C. glabrata [24].     
Also important in the pathogenesis of C. glabrata is its resistance to several 
antifungal drugs, particularly the azole antifungals.  Azoles exist in two classes, 
imidazoles and triazoles, and are the most frequently used antifungal agents due to 
advantages such as selectivity and low toxicity.  Their mode of action is to block the 
biosynthetic pathway of ergosterol, the principle sterol in fungal membranes.  This is 
accomplished by inhibiting the essential enzyme product of the ERG11 gene, lanosterol 
demethylase, the lack of which causes methylated sterols to replace ergosterol in the 
plasma membrane [25].  C. glabrata circumvents this by several mechanisms, but among 
the most important is the ability to transport drugs back out of the cell.  In addition, C. 
glabrata can take up ergosterol precursors such as cholesterol from the host [10].   
Drug resistance is found in several Candida species, but C. glabrata is inherently 
less susceptible to fluconazole than is C. albicans, having a minimal inhibitory 
concentration inhibiting 50% of the yeast population investigated (MIC50) of 16µg/ml, 
compared to 0.25µg/ml in C. albicans.  An increase in the frequency of C. glabrata 
isolates from patients with candidiasis has been associated with fluconazole prophylaxis.  




C. glabrata. Transcription of the gene, CgCDR1, named after a similar gene in C. 
albicans, was increased in azole-resistant isolates of C. glabrata [26].  CgPdr1p is a 
transcription factor that regulates expression of the transporter genes CgCDR1 and 
CgCDR2.  A CgPDR1 deletion will cause an increase in azole susceptibility, but gain of 
function mutations in this gene actually have been shown to increase azole resistance as 
well as the fitness of the organism, increasing its virulence [27].  
Transcriptional Rewiring Among Yeasts 
 
It is well accepted that C. glabrata and S. cerevisiae are very closely related 
phylogenetically, and comparative study of these two species could provide insight into 
why one is increasingly successful in causing infection and the other is nonpathogenic.  It 
is widely believed that a whole genome duplication occurred in the two species’ shared 
lineage.  C. glabrata is thought to have lost the duplicated genes at a faster rate than S. 
cerevisiae [17, 18].  Interestingly, a number of transcription factors were retained in 
duplicate in C. glabrata while only being single-copy in S. cerevisiae, and this has been 
interpreted to suggest that S. cerevisiae may have a simpler transcriptional regulatory 
network than other yeasts [28]. 
Transcriptional rewiring among ascomycetous yeasts is a topic that has garnered 
recent attention after the publication of the genome sequences of many of these yeasts.  
Transcription factors can acquire and lose binding sites relatively quickly, and this 
flexibility could lead to the emergence of new phenotypes.  One such study focused on 
the transcriptional regulator, Mcm1, which has a wide range of functions.  While binding 




lactis (a yeast commonly used in dairy production) and C. albicans, where it binds about 
12% of the genes in both organisms.  When comparing target genes for Mcm1 
homologues in all three species, only about 13%-18% of these genes are shared in 
common among them, so this regulator controls many different genes among the three 
yeasts.  However, the Mcm1p cofactor interactions appear to be better conserved, and 
these authors suggest that while protein sequences remain fairly constant, their regulatory 
network has diverged significantly [29].   
Rewiring of the transcriptional network has also been linked to the differing 
oxygen requirements between S. cerevisiae and C. albicans, with the former preferring 
fermentation even in the presence of oxygen, and the latter being primarily aerobic.  An 
upstream regulatory sequence associated with genes required for rapid growth is 
conserved in both species but is overrepresented in C. albicans in the genes encoding 
mitochondrial ribosomal proteins.  In S. cerevisiae, these genes are induced only during 
environmental stress, suggesting that a change in gene expression could cause this 
phenotypic difference [30]. 
A comparative analysis of whole-genome transcription profiles from S. cerevisiae 
and C. albicans yielded different amounts of conservation among groups of genes 
arranged into Gene Ontology (GO term) categories.  Interestingly, one GO term that was 
not conserved was “regulation of transcription [25].”  Together, these studies imply that 
alterations in gene transcription and in the regulators of gene transcription could drive 




regarding transcriptional rewiring between S. cerevisiae and C. glabrata; however, given 
their close relationship, such a study could prove beneficial. 
Phospholipid Biosynthesis in Saccharomyces cerevisiae 
 
Genetic Control of Phospholipid Biosynthesis 
 
I have found that a C. glabrata homologue of an S. cerevisiae transcriptional 
regulator involved in this process is essential in C. glabrata.  This led to further study of 
phospholipid regulation in C. glabrata and specifically, the de novo pathway of 
phosphatidylinositol biosynthesis.  The S. cerevisiae phospholipid biosynthetic pathway 
and transcriptional regulon have served as a guide in this work, so S. cerevisiae 
phospholipid biosynthesis and regulation are described below. 
Phospholipids are a major component of cellular membranes, but also play a 
number of other roles in yeast cells, including signal transduction and cell surface 
recognition.  The major phospholipids found in S. cerevisiae are phosphatidylinositol 
(PI), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine 
(PS).  The pathways controlling their biosynthesis are both tightly regulated and 
coordinated, which is evidenced in part by all of these phospholipids being either direct 
or indirect products of the precursor phosphatidic acid (PA), which is metabolized to 
form the phospholipid precursors, CDP-diacylglycerol (CDP-DAG) or diacylglycerol 
(DAG) [31] (Figure A.2). 
PE and PC can be synthesized from either of two pathways:  the de novo pathway 




in the de novo pathway is the synthesis of PS from CDP-DAG and free serine, which is 
catalyzed by PS synthase, the product of the CHO1 gene.  PS is then decarboxylated to 
form PE by PS decarboxylase, which is encoded by the genes PSD1 and PSD2.  PE 
undergoes three methylation reactions to form phosphatidyl-monomethyl ethanolamine, 
phosphatidyl-dimethyl ethanolamine, and finally PC.  PE methyltransferase from the 
CHO2 (PEM1) gene is involved in the first reaction, and phospholipid methyltransferase 
from the OPI3 (PEM2)  gene catalyzes the final two [32].   
PE and PC can also be synthesized from exogenous ethanolamine and choline via 
the Kennedy pathway when the enzymes from the de novo pathway are repressed.  The 
enzymes ethanolamine kinase and choline kinase encoded by the EKI1 and CKI1 genes, 
respectively, are responsible for the phosphorylation of ethanolamine and choline.  
Phosphoethanolamine and phosphocholine are then converted to CDP-ethanolamine and 
CDP-choline, respectively, by cytidylyltransferases encoded by the ECT1 and PCT1 
genes.  The final step of this salvage pathway involves the formation of PE and PC 
through a reaction of the products from the second step with DAG [33]. 
PI is synthesized by the enzyme PI-synthase encoded by the PIS1 gene, which 
converts CDP-DAG and inositol to PI.  This is a necessary reaction, and without it, the 
cell cannot live, implying that PI is an essential component of the yeast cell.  PI-synthase 
appears to have constitutive activity independent of the availability of PI precursors and 
this activity also does not change when cells enter stationary phase, in contrast to the 




 Inositol for PI synthesis is derived from exogenous sources or is synthesized de 
novo from glucose-6-phosphate.  The first step of the de novo pathway of PI biosynthesis 
is the conversion of glucose-6-phosphate to inositol-1-phosphate (I1P) by inositol-1-
phosphate synthase.  This enzyme is the product of the INO1 gene.  I1P is subsequently 
dephosphorylated to inositol by inositol monophosphatase, encoded by the INM1 or 
INM2 genes [34].   
INO1 is a highly regulated gene that is repressed in the presence of inositol.  Its 
transcription is activated by a heterodimeric transcriptional activator consisting of Ino2p 
and Ino4p [35].  In the presence of inositol, the transcriptional repressor Opi1p binds to 
Ino2p and prevents transcription of INO1 [36].  OPI1 stands for over-producer of 
inositol, as it was first identified among mutants that secreted inositol into the 
surrounding media [37].  In an opi1 mutant, transcription of INO1 is constitutively 
activated, causing inositol to be produced and excreted [38].  Cells having an ino1, 
ino2, or ino4 mutation are inositol auxotrophs [39] (Figure A.3)  
In the absence of inositol, Opi1p is inactivated by binding to Scs2p, an integral 
membrane protein, and PA, both of which are in the ER.  Inositol is the rate limiting 
component in PI biosynthesis.  The presence of inositol induces the consumption of the 
phospholipid precursor, PA, resulting in the release of Opi1p from the ER and its 
translocation to the nucleus, where it binds Ino2p [40].  Ino2p and Ino4p bind 
constitutively to the promoter of INO1, and are localized to the nucleoplasm under these 




conditions results in the recruitment of INO1 to the nuclear membrane, where 
transcription is activated [41]. 
The inositol regulon controls the expression of many of the enzymes involved in 
phospholipid biosynthesis in response to extracellular inositol and choline levels.  Genes 
that respond to inositol and choline contain an upstream activating sequence (UASINO) in 
their promoters.  This sequence, CATGTGAAAT, has a basic helix loop helix (bHLH) 
binding site, which is essential for it to function as a UAS element and is required for the 
Ino2p of the Ino2p-Ino4p heterodimer to bind to INO1.  This UASINO is also involved in 
the regulatory response to Opi1p.  A systematic substitution of each base pair in the 
UASINO element revealed that this sequence is necessary for optimal function [42].  
UASINO is also found in other genes that are involved in phospholipid biosynthesis and 
inositol-choline response including CHO1, CHO2, CPT1, EPT1, OPI3, PIS1, PSD1, 
INO1, as well as INO2 and INO4 [43].  
Coordinate regulation of Phospholipid Biosynthesis 
 
Evidence exists for the coordinate regulation of phospholipids.  CDP-DAG is 
partitioned within the different phospholipid biosynthetic pathways depending on the 
available precursors.  The presence of exogenous inositol shifts the utilization of CDP-
DAG, causing it to be converted to PI at the expense of PS, PE, and PC via the de novo 
pathway (Figure A.2).  Moreover, inositol serves as an inhibitor of PS synthase, the 
product of the CHO1 gene, also driving metabolism in favor of PI [44].  Conversely, a 
higher concentration of PS synthase can cause CDP-DAG to be consumed, thus altering 




The INO1 gene is the best studied and most highly expressed gene that is 
regulated by the interaction of these pathways.  The level of INO1 mRNA is repressed 
when cells are grown in inositol-containing media.  INO1 is further repressed by the 
addition of choline to cells already growing in inositol; however the addition of choline 
alone caused only a slight increase in the abundance of INO1 RNA [38].  Repression by 
inositol is not limited to the products of INO1 and CHO1, and the activity of CDP-DAG 
synthase, PS decarboxylase and the two N-methyltransferases have all been shown to be 
reduced in the presence of inositol [45].  
An opi1  mutant is known to synthesize INO1 constitutively and independently 
of inositol and choline; however, this mutant also has a high level of CHO1, indicating 
that OPI1 also affects the de novo aminophospholipid pathway.  The phospholipid 
composition of the opi1 mutant remains stable regardless of inositol and choline levels 
compared to that of a wild type cell, which changes depending on the availability of 
inositol and choline.  In addition, the activity of the methyltransferases, which are 
involved in the conversion of PE to PC,  do not fluctuate with varying levels of inositol 
and choline in an opi1 mutant, in contrast to the wild type, further indicating that OPI1 
has a pleiotropic effect on phospholipid regulation [38, 46].   
 INO2 and INO4 are also considered to be pleiotropic in that the phospholipid 
compositions of the ino2 and ino4 mutants have a lower proportion of PC with an 
accumulation of the methylated intermediates involved in the synthesis of PC from PE.  
This suggests that Ino2p and Ino4p are required for maximum expression of the 




the pathway that synthesizes PC in ino2 and ino4 mutants is coupled to an increase in 
the PI composition of the cell.  Similarly, cho1 mutants that cannot synthesize PS have 
higher levels of PI, and ino1 mutants lacking exogenous inositol have increased PS.  
While PI is able to substitute for PS in cho1 mutants, the ino1 mutants under 
conditions of inositol starvation eventually die [32].    
Phospholipid regulation has been shown to affect other cellular functions.  A 
recent study screened mutants having the Opi- phenotype, secreting inositol into the 
growth medium in the absence of inositol and choline.  Among the Opi- mutants were 
genes involved in various processes other than phospholipid biosynthesis such as protein 
processing and trafficking and the unfolded protein response (UPR) [48].  Inositol 
regulation had previously been implicated in the UPR when the transcription factor 
Hac1p, which promotes transcriptional activation of unfolded proteins, was demonstrated 
to be involved with the dissociation of Opi1p from the Ino2p-Ino4p complex [41].      
Another role for the OPI1 gene was recently determined that showed it to be 
involved in the activation of FLO11, which encodes an adhesion protein.  Opi1- mutant 
S. cerevisiae strains were deficient for invasive growth and mat formation; however, the 
mechanism of this regulation remains to be elucidated [49].  The various contributions of 
OPI1 to the cell suggest that it is an important regulator.  The fact that OPI1 has 
homologues in other species, including the close-relative pathogen, C. glabrata, makes it 
a good candidate for further study in this species, especially since OPI1 was shown to 
affect an adhesin, and one of the virulence factors of pathogenic yeast species is their 




On a wider scale, the OPI1 family of genes, which has homologues across many 
fungal species, is gaining attention and becoming better studied in some species and is 
being associated with different functions.  Most recently, the OPI1 homologue in 
Yarrowia lipolytica, YAS3, was determined to play a regulatory role in the transcription 
of ALK1, a gene necessary for the oxidation of n-alkanes.  Yas3p does not regulate the Y. 
lipolytica INO1 homologue, but it does regulate ALK1 in a manner that reflects the 
relationship of Opi1p, Ino2p, and Ino4p in S. cerevisiae.  In particular, Yas3p is a 
repressor of ALK1 that represses transcription by binding to the Yas2p component of the 
Yas1p-Yas2p heterodimeric transcriptional activator.  Yas1p and Yas2p are homologs of 
Ino4p and Ino2p, respectively.   
The sequence of Yas3p is diverged from that of Opi1p (Figure A.4A).  In 
particular, Yas3p lacks some domains that are important for Opi1p including the 
polyglutamine tracts, which are often found in regulatory genes, and the two 
phenylalanines in an acidic tract (FFAT), which allow Scs2p to bind.  Yas3p also lacks 
the Opi1-Sin3 interaction domain by which Opi1p contacts the pleiotropic repressor, 
Sin3p. [50] (Figures A.4A and A.4B).  Interestingly, the Opi1p homologue in Candida 
albicans also lacks similar domains, and like Yas3p, it does not regulate CaINO1 in C. 
albicans (Chen and Reynolds, unpublished data) (Fig A.3A).   
Interestingly, the Opi1p homologue from the much more closely related C. 
glabrata contains all of the important domains that are present in S. cerevisiae Opi1p 
(Figures A.3A and A.3B).  What is more, we show in this thesis that CgOpi1p also 




similar to that found in S. cerevisiae. The surprising contrast is that despite this similarity, 
CgOpi1p is essential in C. glabrata, whereas it is not required for viability in S. 
cerevisiae. This finding is novel among the Opi1p homologuess, and CgOpi1p represents 
the first member of the Opi1p family to control viability. CgOpi1p’s control of viability 
may indicate transcriptional or even metabolic rewiring in C. glabrata compared to S. 
cerevisiae. The work in this thesis project addresses the mechanism by which CgOpi1p 

























This chapter is a paper by the same name submitted for publication in the journal 
Molecular Microbiology in 2009 by Emily K. Bethea, Todd B. Reynolds and Billy 
Carver. 
My contributions to this paper include (1) design of most of the yeast strains, plasmids, 
and primers used in the study, (2) some experimental design, (3) performance of most of 
the experiments, and (4) generation of most of the figures.  
Abstract 
Inositol is essential in eukaryotes, and must be imported or synthesized.  Inositol 
biosynthesis in Saccharomyces cerevisiae is controlled by three nonessential genes that 
make up the inositol regulon: ScINO2 and ScINO4, which together encode a 
heterodimeric transcriptional activator, and ScOPI1, which encodes a transcriptional 
repressor.  ScOpi1p inhibits the ScIno2-ScIno4p activator in response to extracellular 
inositol levels.   An important gene controlled by the inositol regulon is ScINO1, which 
encodes inositol-3-phosphate synthase, a key enzyme in inositol biosynthesis. In the 
pathogenic yeast Candida albicans, homologues of the S. cerevisiae inositol regulon 
genes are “transcriptionally rewired”.  Instead of regulating the CaINO1 gene, CaINO2 
and CaINO4 regulate ribosomal genes.  Another Candida species that is a prevalent cause 
of infections is Candida glabrata; however, C. glabrata is phylogenetically more closely 
related to S. cerevisiae than C. albicans. Experiments were designed to determine if C. 
glabrata homologuess of the inositol regulon genes functioned similarly to S. cerevisiae 
or are transcriptionally rewired. CgINO2, CgINO4, and CgOPI1 regulate CgINO1 in a 
manner similar to that observed in S. cerevisiae.  However, unlike in S. cerevisiae, 
CgOPI1 is essential.  Genetic data indicate that CgOPI1 is a repressor that affects 






Fungi of the genus Candida are the most common cause of human fungal 
infections and can lead to both mucosal and systemic infections [51].  Candida albicans 
is the most common cause of these infections, but non-albicans Candida species are 
increasingly associated with disease [52].  One of these non-albicans species, Candida 
glabrata is now the second most common cause of both mucosal and systemic Candida 
infections [15].  
 Phylogenetically, Candida glabrata is more closely related to the non-pathogenic 
yeast Saccharomyces cerevisiae than most of the other common species of Candida 
associated with human disease [15].  C. glabrata lacks a number of the virulence factors 
associated with Candida pathogens such as secreted hydrolases and hyphal growth [15].  
Despite this, C. glabrata is a growing challenge in clinical settings where it causes 
mucosal infections and is associated with approximately 15% of all Candida-related 
systemic bloodstream infections [53].  These observations are interesting in light of the 
fact that C. glabrata is more closely related to S. cerevisiae, but it is still a pathogen 
whereas S. cerevisiae is only very, very rarely associated with infection [54].  A clearer 
understanding of how S. cerevisiae and C. glabrata differ from one another may help 
shed light on why one is a significant human pathogen and the other is not. 
 A number of recent studies have shown that Candida albicans is transcriptionally 
rewired compared to S. cerevisiae.  For example, the genes encoding enzymes of the 
Leloir pathway for galactose catabolism in S. cerevisiae are regulated by the ScGal4p 




transcription factor Cph1p, while the C. albicans CaGal4p homologue regulates TCA 
cycle genes such as CaLAT1 [55].  Other examples of transcriptional rewiring between C. 
albicans and S. cerevisiae include regulatory systems controlling mating type [56], 
mitochondrial ribosomal genes [30], and de novo myo-inositol biosynthesis genes [57], 
(Chen and Reynolds, unpublished data). Myo-inositol will be referred to as inositol 
throughout the rest of this article. 
 Since there are several examples of transcriptional rewiring between these two 
more distantly related yeasts (S. cerevisiae and C. albicans), it was of interest to 
determine if similar rewiring is present between the more closely related yeasts C. 
glabrata and S. cerevisiae.  The Leloir enzymes for galactose metabolism are not present 
in C. glabrata, and this yeast is unable to utilize galactose [58], so this pathway is 
unavailable for comparison.  Mating has never been described for C. glabrata, thus this 
pathway is not useful for study either.  In contrast to these pathways, the inositol regulon 
appears to be an excellent pathway to compare between these two yeasts.  The inositol 
regulon is a very well studied transcriptional regulon in S. cerevisiae (reviewed in [43, 
59]), and there are C. glabrata orthologs for both the transcription factors and targets of 
the S. cerevisiae inositol regulon (see results and discussion).   
 The inositol regulon in S. cerevisiae has been well-described [43, 59], and 
consists of three main transcription factors that regulate target gene expression in 
response to extracellular inositol levels (Fig 1).  The roles of each of these transcription 
factors in controlling this regulon are described in more detail below.  Transcriptional 




the most highly expressed and well-characterized of these targets is the Saccharomyces 
cerevisiae INO1 (ScINO1) gene.  ScINO1 encodes an enzyme that occupies the rate-
limiting step in de novo inositol biosynthesis.  Inositol is essential and is required for the 
synthesis of phosphatidylinositol (PI) which is a precursor for several essential lipids 
including inositol-phosphate signaling lipids, glycosylphosphatidylinositol (GPI) anchors, 
and sphingolipids [60] [61].    
ScIno1p is an inositol-3-phosphate synthase which converts glucose-6-phosphate 
to inositol-3-phosphate [62].  Inositol-3-phosphate is dephosphorylated by the inositol 
monophosphatases ScInm1p or ScInm2p to create inositol [34].  An Scino1∆ mutant 
cannot make inositol de novo and is an inositol auxotroph. In the absence of extracellular 
inositol (or at low concentrations like 10µM) ScINO1 is expressed, and in the presence of 
higher concentrations of extracellular inositol ScINO1 is repressed [63] (Fig 1).  
The inositol regulon transcription factors ScIno2p and ScIno4p form a 
heterodimeric transcriptional activator that binds to the upstream activator sequence 
(UASINO) in the promoters of target genes such as ScINO1 [35, 42, 64-66]. Both ScIno2p 
and ScIno4p are absolutely required for transcription of ScINO1, so Scino2∆ and Scino4∆ 
mutants are inositol auxotrophs.     
The regulation of ScINO1 in response to extracellular inositol is dependent on the 
repressor protein ScOpi1p [40, 67-70].  ScOpi1p senses the level of extracellular inositol 
indirectly based on the level of the PI precursor lipid phosphatidic acid (PA).  Inositol is 
the rate-limiting metabolite in PI synthesis, and when there is abundant extracellular 




during synthesis of PI.  In these conditions ScOpi1p binds to ScIno2p and represses 
transcription of ScINO1.  When extracellular inositol is not available or is greatly 
decreased, PI synthesis slows, and PA levels increase in the endoplasmic reticulum (ER).  
ScOpi1p, which binds to PA, is recruited to ER where it binds PA and the ER protein 
Scs2p. Thus, the ScIno2p-ScIno4p heterodimer is free to transcribe ScINO1.  A mutation 
that deletes ScOPI1 results in constitutive overexpression of ScINO1 and of other genes 
carrying the UASINO sequence in their promoters.  
The purpose of this study was to determine if C. glabrata carried an inositol 
regulon that is similar to that in S. cerevisiae, or if these yeasts are transcriptionally 
rewired for inositol regulation. In order to do this, C. glabrata homologues of the S. 
cerevisiae inositol regulon proteins were identified and disrupted.   Analysis of these 
mutants revealed the surprising finding that CgOPI1 is essential for growth under the 
experimental conditions used in this study.  CgIno2p and CgIno4p (which are not 
essential) are activators of CgINO1, and CgOpi1p is a transcriptional repressor of 
CgINO1, like the situation in S. cerevisiae. However, unlike in S. cerevisiae, CgOPI1 is 
required for viability.  This difference from S. cerevisiae may indicate that the inositol 
regulon in C. glabrata has some additional or different targets than bakers’ yeast, or C. 








CgINO2 and CgINO4 encode transcriptional activators of the CgINO1 gene and 
control de novo inositol biosynthesis 
 
A homologue of ScINO1 was identified in C. glabrata by BLASTing the ScINO1 
translated protein sequence against the Candida glabrata genome at the Genolevures 
website (http://cbi.labri.fr/Genolevures/elt/CAGL).  The BLAST search revealed that the 
gene CAGL0I06050g encoded a protein that was 73.9% identical to ScIno1p.  We refer to 
CAGL0I06050g as CgINO1 based on the experiments described below.  
CgINO1 expression was examined in media containing or lacking inositol by 
Northern blotting which revealed that CgINO1 was highly expressed in medium lacking 
inositol, but it was not expressed in medium containing 75µM inositol (Fig 3). This is 
similar to what has been observed for ScINO1 in S. cerevisiae [19, 63, 71].  In order to 
determine if CgINO1 was required for de novo inositol biosynthesis, the CgINO1 open 
reading frame (ORF) was disrupted by homologous recombination using a two-step gene 
deletion strategy (Supplemental figure 1 and methods and materials) [19, 71].  The 
resulting Cgino1∆ mutant was unable to grow on inositol-free medium (Fig 2).  However, 
when the CgINO1 gene was reintegrated into the genome at the CgINO1 locus, the 
reconstituted strain (Cgino1∆::CgINO1) could grow in medium lacking inositol (Fig 2). 
The CgINO1 gene is regulated in a similar manner as the ScINO1 gene in 
synthetic medium containing or lacking inositol which suggested that the inositol regulon 
that controls ScINO1 in S. cerevisiae might be conserved in C. glabrata.  In order to test 
this, homologues of the ScINO2 and ScINO4 transcriptional activator genes were 
identified by BLAST searches querying the protein sequences of ScIno2p and ScIno4p 




(http://cbi.labri.fr/Genolevures/elt/CAGL).  The BLAST searches revealed only one 
strong homologue for each protein, and these were encoded by the genes 
CAGL0B01947g for ScIno2p (35.6% identity) and CAGL0I07359g for ScIno4p (44.5% 
identity).  These genes, CAGL0B01947g and CAGL0I07359g, were named CgINO2 and 
CgINO4, respectively. CgINO2 and CgINO4 were disrupted using the two-step gene 
disruption method which completely removed the ORF of each gene.  The resulting 
Cgino2∆ and Cgino4∆ mutants were tested to determine if they could grow in the 
absence of inositol in the medium.  As seen for orthologous Saccharomyces mutants, the 
Cgino2∆ and Cgino4∆ mutants were unable to grow on inositol-free medium (Fig 2).  
These data suggested that CgINO2 and CgINO4 controlled the expression of the CgINO1 
gene.  Northern blotting revealed that Cgino2∆ and Cgino4∆ mutants showed a complete 
lack of CgINO1 expression even in inositol-free medium (Figure 3).  Reconstituted 
Cgino2∆::CgINO2 and Cgino4∆::CgINO4 strains, conversely, grew well on medium 
lacking inositol (Fig 2) and regulated CgINO1 much like the wild-type strain (Fig 3).   
 
CgOPI1 encodes an essential gene in Candida glabrata 
 
 In S. cerevisiae the ScOPI1 gene encodes the main regulator of de novo inositol 
biosynthesis in Saccharomyces, and its homologue was identified in a BLAST search 
against the C. glabrata genome at Genolevures as described above.  The protein encoded 
by CAGL0K03267g was found to be 52.3% identical to ScOpi1p.  An attempt was made 
to disrupt the CgOPI1 gene by the two-step gene disruption strategy; however, this 




The above results suggested that CgOPI1 might be essential.  This was tested by 
the strategy described in figure 4. The CgOPI1 gene along with non-coding DNA 
flanking both 5’ and 3’ of the ORF (including the transcriptional promoter and 
terminator, respectively) were cloned into the single-copy CEN/ARS vector pGRB2.1 
[72], which is marked with the S. cerevisiae URA3 gene, to create the plasmid pCgOPI1.  
The pCgOPI1 plasmid was transformed into the wild-type strain, and the chromosomal 
CgOPI1 ORF was disrupted by homologous recombination using the construct described 
in figure 4 that contains the nourseothricin resistance marker NAT1 [73].  The resulting 
pCgOPI1 Cgopi1∆ strain was then streaked onto medium containing 5-fluoroorotic acid 
(5-FOA).  Processing of 5-FOA by the URA3 gene product from S. cerevisiae or C. 
glabrata leads to production of 5-fluorodeoxyuridine which is toxic to C.glabrata [71, 
74].   
If the Cgopi1∆ mutation is lethal, then no Cgopi1∆ pCgOPI1 colonies should 
grow on 5-FOA medium because the 5-FOA would select against the cells carrying 
pCgOPI1.  In figure 5 it is clear that the Cgopi1∆ pCgOPI1 strain cannot grow on 5-FOA.  
In contrast, the parental strain carrying either pCgOPI1 or the empty vector grew well on 
this medium.   
These experiments were performed in the strain background BG2 [71], and there 
was concern that this phenotype was strain-specific.  In order to rule this out, the above 
strategy was used to test the essentiality of CgOPI1 in the strain background ATCC 2001 




strain as well, which suggested that the essentiality of CgOPI1 is not just a BG2 strain-
specific phenomenon (data not shown). 
 
The regulation of viability by CgOPI1 is dependent on the CgINO2 transcription 
factor 
 
Based on the model from S. cerevisiae (Fig 1), it was hypothesized that disruption 
of CgOPI1 causes overexpression of a downstream target of the inositol regulon that then 
results in a loss of viability.  In S. cerevisiae, overexpression of ScINO1 in the Scopi1∆ 
mutant is due to unrepressed transcriptional activation by ScIno2p (Fig 1).  The Scopi1∆ 
mutant’s ScINO1 overexpression phenotype can be blocked by a Scino2∆ mutation.  The 
Scopi1∆ Scino2∆ double mutant acts like the Scino2∆ single mutant and fails to express 
ScINO1 because the Scino2∆ mutation is epistatic to the Scopi1∆ mutation [63].   
If the Cgopi1∆ mutant compromises viability due to overexpression of a 
downstream target of CgIno2p, then a Cgino2∆ mutation should restore the viability of a 
Cgopi1∆ mutant by blocking expression of this putative target.  In order to test this 
hypothesis, the Cgino2∆ mutant was transformed with the pCgOPI1 plasmid, and the 
chromosomal ORF of CgOPI1 was disrupted as described (Figure 4).   The resulting 
Cgopi1∆ Cgino2∆ pCgOPI1 strain was streaked on 5-FOA medium, and it was found to 
grow like the wild-type strain carrying pCgOPI1 or empty vector (Fig 6).  The Cgino2∆ 





The CgOPI1 gene product represses expression of CgINO1 
 
The results above suggest that CgOPI1 can act as a repressor of CgINO2 targets 
such as CgINO1.  In order to determine if CgOPI1 could repress CgINO1, CgOPI1 was 
place under the control of a doxycycline repressible promoter [75].  The C. glabrata 
BG14 strain (Cgura3∆) was modified by disrupting both the CgHIS3 gene (making it a 
histidine auxotroph) and the CgTRP1 gene (making it a tryptophan auxotroph). Using the 
resulting triple auxotroph (Cgura3∆ Cghis3∆ Cgtrp1∆), the promoter of the CgOPI1 
gene was replaced on the chromosome by homologous recombination with the tetO-
HOP1 promoter construct derived from plasmid p97CGH (CgHIS3) [75].  This strain was 
further modified by integration of the pINTG4 plasmid (CgTRP1) carrying the 
tetR::GAL4AD repressor-activator that activates the tetO-HOP1 chimeric promoter in the 
absence of doxycycline, but represses it in the presence of doxycycline. 
The resulting strain was then tested for growth in the presence and absence of 
doxycycline, and it was found that this strain showed very poor growth in 10µg/ml 
doxycycline, but grew quite well in the absence of doxycycline (Fig 7B).  These 
experiments were performed on synthetic minimal medium, but similar results were seen 
in YPD (rich) medium (E. Bethea and T. B. Reynolds, data not shown).  When CgOPI1 
levels were assessed in this strain by Northern blot, it was found that CgOPI1 was 
expressed in the absence of doxycycline, but was not expressed in the presence of drug 
(Fig 7A).   
CgOpi1p acts as a repressor of CgINO1 expression as measured by Northern 




CgINO1 expression increases substantially, but when CgOPI1 is expressed in the absence 
of doxycycline, then CgINO1 expression is very low or undetectable (Fig 7A).  This 
indicates that CgOpi1p acts as a repressor of CgINO1.  We were also able to demonstrate 
the regulation of CgINO1 expression by CgOpi1p using the C. glabrata copper-inducible 
MTII promoter [76] as well (E. Bethea and T. B. Reynolds, data not shown).  
  
Overexpression of CgINO1 is not responsible for the loss of viability in the Cgopi1∆ 
mutant 
 
Since CgINO1 is overexpressed in the absence of CgOPI1, it seemed possible that 
CgINO1 overexpression is responsible for the loss of viability.  This was tested by 
creating a Cgopi1∆ Cgino1∆ pCgOPI1 double mutant.  However, when this double 
mutant is streaked onto 5-FOA it fails to grow (data not shown) indicating that the 
disruption of CgINO1 is not sufficient to restore viability as seen with CgINO2 (Fig 6).   
 
CgCHO1 and CgOPI3 show altered gene expression in the CgOPI1-tetO strain 
 
 Genes that respond to inositol and choline in S. cerevisiae have an upstream 
activating sequence in their promoters called the UASINO.  This sequence is found in 
OPI1 as well as INO2, INO4, and INO1.  It is also found in five genes in C. glabrata, 
including CgCHO1, CgOPI3, CgCHO2, CgINO1, and CgITR2.  A northern blot analysis 
was performed using the strain containing the CgOPI1-tetO fusion in order to see if these 
two genes might be influenced by CgOPI1.  It was found that under conditions of 





Transcriptional rewiring has been suggested between the inositol regulons of S. 
cerevisiae and C. albicans, based on the observations that CaINO2 and CaINO4 genes 
cannot regulate the CaINO1 gene in a heterologous expression system in S. cerevisiae 
[57].  In addition, the CaIno2p and CaIno4p proteins do not appear to bind to the CaINO1 
promoter, which contrasts with ScIno2p and ScIno4p that bind the ScINO1 promoter. 
Interestingly, the CaIno2p-CaIno4p complex appears to bind to a sequence in the 
promoters of several rRNA genes in C. albicans. It has even been suggested that CaINO2 
and CaINO4 are essential in C. albicans based on the fact that only heterozygous mutants 
could be made.  However, this result is not definitive as a conditional promoter was not 
used to confirm these assertions.  Additional support for the hypothesis that the inositol 
regulon in C. albicans is rewired compared to S. cerevisiae is provided by the fact that 
the CaOPI1 gene does not affect the expression of CaINO1 (Chen and Reynolds, 
manuscript in preparation).   
 Candida glabrata is much more closely related to S. cerevisiae than C. albicans 
based on phylogenetic trees comparing 18S ribosomal sequences [15].  Our analysis 
suggests that the C. glabrata inositol regulon is not transcriptionally rewired compared to 
S. cerevisiae, at least for CgINO1 regulation.  However, a major difference between the 
two species is that the OPI1 homologue in C. glabrata appears to be essential, whereas it 
is not for S. cerevisiae. This result suggests that there are important differences between 
S. cerevisiae either in downstream targets of the Opi1p homologues or in the lipid 




BLAST searches against the C. glabrata genome revealed that it contained 
homologues of the S. cerevisiae inositol regulon components and the ScINO1 gene.  Gene 
disruption studies revealed that the CgINO1 gene is required for de novo inositol 
biosynthesis indicating that it is the C. glabrata inositol-3-phosphate synthase gene (Fig 
2). CgINO2 and CgINO4 encode orthologs of the S. cerevisiae inositol regulon 
components as they are required for CgINO1 transcription and de novo inositol 
biosynthesis (Figs 2 and 3).  When the expression of the CgOPI1 gene was repressed 
using the doxycycline repressible promoter system, the CgINO1 gene was overexpressed 
compared to the wild-type strain, indicating that CgOpi1p is a transcriptional repressor of 
CgINO1 (Fig 7A).   
The most interesting observation, however, was that CgOPI1 appears to be 
essential for viability.  Reduction of expression of the CgOPI1 gene using the 
doxycycline repressible promoter prevented growth on solid agar medium (Fig 7) and 
decreased growth in liquid medium (data not shown).      
It is not clear how CgOpi1p controls viability, but our data suggest that it causes a 
loss of viability by overexpressing a downstream target of CgIno2p-CgIno4p.  We found 
that a mutation of CgINO2 can rescue the Cgopi1∆ mutant’s viability defect (Fig 6).  
A model to explain this rescue of viability by the Cgino2∆ mutation is derived 
from the inositol regulon in S. cerevisae. The ScINO2 gene has been shown to be 
epistatic to ScOPI1 for the regulation of ScINO1 and inositol biosynthesis [63].  The 
Scopi1∆ mutant overexpresses ScINO1 and the Scino2∆ mutant fails to express ScINO1.  




express ScINO1.  ScOpi1p is the primary regulator of this regulon, and in a Scopi1∆ 
mutant the ScIno2p-ScIno4p complex constitutively activates target genes resulting in 
overexpression of ScINO1.  ScIno2p is absolutely required for target gene expression, 
thus a Scino2∆ disruption blocks ScINO1 expression even if ScOPI1 is disrupted.  
Using this model as a guide, it would appear that the Cgopi1∆ mutation causes 
overexpression of CgIno2p target genes and one of these targets causes a loss in viability 
when overexpressed.  Disruption of CgINO2 in the Cgopi1∆ strain rescues growth of the 
Cgopi1∆ mutant because the downstream target is no longer overexpressed.   
One possible target appeared to be CgINO1, however disruption of CgINO1 in the 
Cgopi1∆ strain did not rescue viability on 5-FOA plates indicating that CgINO1 
overexpression is not toxic.   
There are two main models to explain the Cgopi1∆ mutant’s loss of viability.   1)  
A direct downstream target gene involved in phospholipid biosynthesis is overexpressed, 
and C. glabrata is particularly sensitive to this imbalance in lipid biosynthesis and loses 
viability.  2)  Expression of a direct target gene not involved in lipid biosynthesis is 
affected by Cgopi1∆ and results in a loss of viability.  
In the first model, there are several phospholipid biosynthetic genes that may be 
targets of the C. glabrata inositol regulon based on sequence similarity to homologues in 
S. cerevisiae.   Direct downstream targets of the S. cerevisiae inositol regulon have been 
identified by the presence of the UASINO consensus sequence CATGTGAAAT in their 
promoters and their misregulation in Scino2∆, Scino4∆, and Scopi1∆ mutants [63, 77-80]. 




CATGTG (the most important part of the UASINO consensus sequence [43]) in their 
promoters.  These genes include CgINO1, CgOPI3, CgCHO1, CgCHO2, and CgITR2.  In 
addition to these five genes, two other genes, CgERG20 and CgCKI1, contain the 
sequence CATGTT, which differs by only one base and could possibly also respond to 
the inositol regulon.  Preliminary data involving CgOPI3 and CgCHO1 (Fig 9) indicate 
that this model could be correct; however, further experiments including the creation of 
double-knockout strains of CgOPI1 and each of these genes must be performed to 
provide support for this hypothesis.   
In the second model, the target may be unrelated to phospholipid biosynthesis 
and/or may not have a homologue that is regulated by the inositol regulon in S. 
cerevisiae.  Such a gene might also not be the direct cause of the loss of viability, but 
might itself regulate a downstream effector and cause the loss of viability.  For example, 
if CgOPI1 were to repress a transcriptional repressor of an essential gene then loss of 
CgOPI1 could result in loss of expression of the essential gene and compromise viability.   
We are currently investigating these different possibilities in order to elucidate the 











Strains and media 
 
Strains are listed in Table 1.  Integrations and manipulations were confirmed by 
PCR (Table 2) in most cases and by Southern blotting with the tetO::HOP1::CgOPI1 
strain. The BG14 strain, which is a uracil auxotroph (Table 1), was a gift from Brendan 
Cormack and was used to generate all of the strains reported in this study.  Disruption of 
CgINO2, CgINO4, and CgINO1 was performed in BG14 (Table 1) utilizing the two-step 
gene disruption strategy [19, 71, 81] with disruption constructs built in the pRS306 vector 
[82] (Table 3) carrying the ScURA3 marker that can be selected for on media lacking 
uracil and counter-selected against using media containing 5-FOA (supplemental figure 
1).  Reintgrates of each of these gene disruption mutants were made by transforming the 
strains with ScURA3-marked integrating plasmids carrying the wild-type gene (Table 3).   
 The Cgopi1∆ mutant (Table 1) was generated in BG14 by transforming it with the 
pCgOPI1 episomal plasmid (ScURA3 marker, Table 3), and then disrupting the CgOPI1 
gene with the Cgopi1::NAT1 construct amplified from plasmid pCgopi1∆ (Table 3).  The 
Cgopi1∆ Cgino2∆ double mutant was made in the same manner as the Cgopi1∆ mutant 
except it was done in the Cg5 (Cgino2∆) strain.    
 The tetO::HOP1::CgOPI1 strain EBCg048 (Table 1) was generated by first 
making BG14 a histidine and tryptophan auxtotroph (Cghis3∆ Cgtrp1∆).  This was done 
by disrupting CgHIS3 in BG14 as described above for the Cgino2∆ gene to create the 
Cg33 strain. The CgTRP1 gene was disrupted in Cg33 using a plasmid from Karl 




tetO::HOPI1::CgOPI1 strain EBCg048 by first integrating the pINTG4 plasmid carrying 
the tetR::GAL4AD repressor-activator into its genome as described [75].  Then the 
tetO::HOP1::CgOPI1 construct was PCR amplified from plasmid pEB48 (Table 3) and 
was used to replace the CgOPI1 locus on the chromosome. 
  Media used in this study included 2% agar plates or liquid medium made with 
YPD, YNB, or inositol free media [83] with the supplements of amino acids, nucleotides, 
inositol, doxycycline, 5-fluororotic acid (5-FOA), etc as described in the text.  For 
inositol-free media Bactoagar was used because it does not contain trace amounts of 
inositol.  
 
Plasmids and constructs 
 
The gene disruption plasmids (pRS306-ino2∆, pRS306-ino4∆, and pRS306-
ino1∆) were made by PCR amplifying DNA corresponding to approximately 500 
basepairs of noncoding DNA that flanked the 5’ and 3’ edges of each open reading frame 
(5’ or 3’-NCRs), and then cloning them into pRS306 adjacent to one another to create a 
disrupted allele (primers and restriction sites used for cloning are listed in Table 2).  The 
pRS306-his3∆ disruption plasmid was created in a similar manner by subcloning the 
CgHIS3 5’-NCR into the plasmid pGRB2.1 [72] upstream of the 3’NCR of CgHIS3 
contained in this plasmid.  The whole 5’ and 3’-NCR disruption cassette was then 
subcloned into the pRS306 integrating vector [82] as an XbaI-KpnI fragment to create 
pRS306-his3∆.   The disrupted alleles from all of the pRS306 disruption cassette 




BG14 by the two-step deletion strategy [19, 71, 81].  For example, the pRS306-ino1∆ 
cassette was cut with NruI in the 5’-NCR to linearize it and target it to recombine 
upstream of CgINO1 (Figure 7).  PCR was used to confirm correct integration, and 
disruption.  In a similar manner, the pRS306-ino4∆, pRS306-ino1∆, and pRS306-his3∆ 
plasmids were cut with PmlI, SnaBI and BglII respectively.  Following replacement of 
the wild-type genes with the disrupted alleles, the mutant alleles were confirmed based on 
phenotype and PCR.  Reintegration constructs were generated for each of the above 
disruptants in the vector pRS306 by PCR amplifying the corresponding ORFs plus ~500 
basepair 5’ and 3’-NCRs with the primers BCO3 and BCO2 for CgINO2, USO1 and 
USO4 for CgINO4, and MHO3 and MHO2 for CgINO1.  Cut sites for subcloning are 
listed in Table 2. Plasmids were linearized with the enzymes sites mentioned above, and 
transformed into their respective disruptant strains.  Correct integrations were confirmed 
by PCR with primers listed in Table 2.   
 The episomal pCgOPI1 plasmid carrying CgOPI1 plus 215 basepairs of upstream 
DNA and 439 basepairs of downstream DNA was generated by amplifying the CgOPI1 
ORF and flanking sequences from purified BG14 DNA using primers TRO605 and 
TRO608, and cutting the PCR product with BamHI and SpeI enzymes.  The SpeI site was 
introduced by primer TRO608 and the BamHI site was internal to the amplified DNA 
fragment.  This PCR product was cloned into the ScURA3 bearing C. glabrata CEN/ARS 
plasmid pGRB2.1 [72] using SpeI and BamHI.  The Cgopi1∆ plasmid was generated by 
subcloning the NAT1 cassette from pAG25 [73] with primers TRO652 and TRO653 into 




(cloned in by primers TRO605 and TRO606) and a 439 basepair fragment containing the 
3’-NCR of CgOPI1 (cloned in by primers TRO607 and TRO608) both carried on the 
pRS306 vector.  The pINT4 vector was a gift from Hironobu Nakayama [75] and was 
integrated into the EBCg046 genome after cutting it with EcoRV [75].  The pEB48 
plasmid was generated by subcloning an ~500 basepair 5’-NCR of the CgOPI1 ORF into 
p97CGH upstream (5’) of the HIS3 tetO-HOP1  cassette using primers EBO76 and 
EBO77.  The CgOPI1 ORF was then subcloned 3’ to the HIS3 tetO-HOP1 cassette using 
a PCR product made by primers EBO64 and EBO65.  This whole segment from pEB48 
containing 5’-CgOPI1 promoter-HIS3 tetO-HOP1-CgOPI1 ORF was then transformed 





Northern blotting was performed essentially as described [49] using probes 
generated from primers EBO40 and EBO41 for CgINO1, EBO11 and EBO12 for 
CgOPI1, TRO656 and TRO636 for CgACT1, EBO56 and EBO57 for CgCHO1, EBO54 





























Appendix 1: Tables 
 
Table 1.  Strains used in this study 
Strains  Genotype Reference 
BG14 Cgura3::Tn903neoR [71]  
Cg11 Cgura3::Tn903neoR pCgOPI1 This study 
Cg12 Cgura3::Tn903neoR pGRB2.1 This study 
Cg14 Cgura3::Tn903neoR Cgopi1∆ pCgOPI1 This study 
Cg5 Cgura3::Tn903neoR Cgino2∆ This study 
EBCg019 Cgura3::Tn903neoR Cgino2::CgINO2 This study 
Cg23 Cgura3::Tn903neoR Cgino2∆ pCgOPI1 This study 
Cg18 Cgura3::Tn903neoR Cgino2∆ Cgopi1∆ pCgOPI1 This study 
EBCg005 Cgura3::Tn903neoR Cgino4 This study 
EBCg008 Cgura3::Tn903neoR Cgino4::CgINO4 This study 
EBCg014 Cgura3::Tn903neoR Cgino1 This study 
EBCg017 Cgura3::Tn903neoR Cgino1::CgINO1 This study 
Cg33 Cgura3::Tn903neoR Cghis3∆ This study 
EBCg046 Cgura3::Tn903neoR Cghis3 Cgtrp1∆ This study 
EBCg048 Cgura3::Tn903neoR Cghis3 Cgtrp1∆ pINTG4 pEB48 This study 






























Table 2.  Primers used in this study 
Primer Sequence Restriction  
site  
Purpose 
TRO605 AAAAAAGCTTTGCCTCCTTATCGGTAACAAa HindIII Forward for 5’NCRb of CgOPI1l 
TRO606 AAAAGAATTCTCCAGCAGCACAGTTTATTCA EcoRI Reverse for 5’NCR of CgOPI1l 
TRO607 AAAAGAATTCCTCTTCAAATTGAAAACGTTACGAC EcoRI Forward for 3’NCR of CgOPI1l 
TRO608 AAAAACTAGTGATTTCTGTTTGACTATTGGTTCTC SpeI Reverse for 3’NCR of CgOPI1l 
TRO652 AAAAGAATTCCAGCTGAAGCTTCGTACGC EcoRI Forward for NAT1 gene 
TRO653 AAAAGAATTCGCATAGGCCACTAGTGGATCTG EcoRI Reverse for NAT1 gene 
VSO1 AAAACTCGAGCCTTTACACCTGTGAACTACAGTCA Xho1 Forward for 5’ NCR CgINO4 
VSO2 AAAAGAATTCTCCGACTTTTGAAATGGGGT EcoR1 Reverse for 5’ NCR CgINO4 
VSO3 AAAAGAATTCTGCCTGTAATTGAGAAATCCTATTG EcoR1 Forward for 3’ NCR CgINO4 
VSO4 AAAAGGATCCTTGAAAAGAGAAGTTAAAACAGAGG BamH1 Reverse for 3’ NCR CgINO4 
MHO3 AAAACTCGAGTGTCCCCTTTTTTTTTGCC Xho1 Forward for 5’ NCR CgINO1 
MHO4 AAAACCCGGGTCGTGTGGTAAGTGTAGTTGGTCA Sma1 Reverse for 5’ NCR CgINO1 
MHO1 AAAACCCGGGCAGACTTCCCAATGAGGGAAA Sma1 Forward for 3’ NCR CgINO1 
MHO2 AAAACCGCGGCGTTCGTTGGCGAAACTTTT SacII Reverse for 3’ NCR CgINO1 
BCO3 AAAAAAGCTTTCGCCCGTCTGAAAAAAA HindIII Forward for 5’ NCR of CgINO2 
BCO4 AAAAGAATTCGGTTCGTGTATTAAATTAAGCACTC EcoR1 Reverse for 5’ NCR of CgINO2 
BCO1 AAAAGAATTCCTACTGACTGTATGTTAGGCTGCAA EcoR1 Forward for 3’ NCR of CgINO2 
BCO2 AAAAGGATCCCAAACTCTTCTTTGAATGACTTTG BamH1 Reverse for 3’ NCR of CgINO2 
TRO665 AAAATCTAGAATTCCCCCATGTACCACAGTC XbaI Forward for 5’ NCR of CgHIS3 
TRO667 AAAAGGATCCTTGCTCGATGCTTCTCTTTG BamHI Reverse for 5’ NCR of CgHIS3 
EBO24 GTTGCTGTTAAGTATGTTTGA  Check insertion of pEB13 (ino4∆) 
EBO27 TGGCAACTAGAATTTTTCACATGC  Check insertion of pEB19 (ino1∆) 
TRO668 TACGTTGTTACCCACACGATT  Check insertion of pRS306-his3∆ 
TRO623 ACAGTCATCCAAAGGTGACTCTCAT  Check insertion of pRS306-ino2∆ 
TRO536 CCAGGGTTTTCCCAGTCA  Reverse for primers EBO24, EBO27, 
and TRO623 
TRO614 GAAGGAATCTCAAAAGTGCGGA  Check insertion of pCgopi1∆ 
TRO461 GTGCGCAGAAAGTAATATC  Reverse primer for TRO614 
EBO64 AAAAGAATTCACCATGGACACAAGGCGTG EcoR1 Forward for CgOPI1 tetO promoter 
EBO 65 AAAAGGGCCCGTAGATGTAGGTTCTCCTTTTCATTA Apa1 Reverse for CgOPI1 tetO promoter 
EBO40 ATGACTGTGAATAAAGGTATTAGCATTC  Forward for CgINO1 probe 
EBO41 CTATTTCAATCTTTCTTCGAATCTCAG  Reverse for CgINO1 probe 
TRO656 GCCGGTTTCGCCGGTGACG  Forward for CgACT1 probe 
TRO636 CCAAAGCGACGTAACATAGCTTT  Reverse for CgACT1 probe 
EBO12 GACACAAGGCGTGGGTG  Forward for CgOPI1 probe 
EBO11 TCATACCTTTTGTAAATGCATA  Reverse for CgOPI1 probe 
a Underline shows the restriction site 






 Table 3.  Plasmids used in this study. 
Plasmid description type restriction site Reference 
pRS306-ino2∆ CgINO2 knockout integrating SnaBI This study 
pRS306-CgINO2 CgINO2 reintegration  integrating SnaBI This study 
pEB19 CgINO1 knockout  integrating Nru1 This study 
pEB21 CgINO1 reintegration integrating Nru1 This study 
pEB13 CgINO4 knockout integrating Pml1 This study 
pEB17 CgINO4 reintegration integrating Pml1 This study 
pCgOPI1 contains CgOPI1 episomal  This study 
pCgopi1∆ Cgopi1∆ integrating  This study 
pRS306-his3∆ CgHIS3 knockout integrating BglII This study 
pGRB2.1 ScURA3 vector episomal  [72] 
pAG25 NAT1 cassette PCR template  [73] 
pEB48 tetO::HOP1::CgOPI1  Integrating  This study 
pINTG4 tetR::GAL4AD Integrating  [75] 






























Appendix 2: Figures 
 
 
Figure 1. The Inositol Regulon in S. cerevisiae.   
 
 The inositol regulon in S. cerevisiae controls transcription of phospholipid 
biosynthetic genes like ScINO1 in response to the level of extracellular inositol.  
(A) The ScIno2p-ScIno4p heterodimer activates transcription of ScINO1 and 
other target genes in the absence of extracellular inositol. ScIno2p-ScIno4p  binds 
the upstream activating sequence for inositol regulation (UASINO) present in the 
promoters of genes like ScINO1. (B)  In the presence of extracellular inositol 
ScOpi1p binds to ScIno2p and prevents it from activating transcription of ScINO1 








Figure 2.  Inositol Auxotrophy of Cgino1, Cgino2, and Cgino4.   
 
 The CgINO1, CgINO2, and CgINO4 genes are all involved in de novo inositol 
biosynthesis, like their S. cerevisiae homologuess.  The Cgino1∆, Cgino2∆, and 
Cgino4∆ mutants and their respective reconstituted strains (along with the wild-
type control) were streaked onto inositol free media supplemented with 0 or 










Figure 3.  CgINO1 Expression in Mutants.   
 
 CgINO2 and CgINO4 are required to express CgINO1 in the absence of 
exogenous inositol. Northern blotting was used to assess the expression of 
CgINO1 in wild-type (WT), mutant, and reconstituted strains in the presence or 
absence of exogenous inositol.  CgACT1 was used as a loading control.  Strains 
were grown overnight at 30˚C in inositol-free medium supplemented with 75µM 
inositol, washed with water, and resupended in inositol-free media containing 
either 0 or 75µM inositol, after which the cultures were incubated with shaking 











Figure 4.  Diagram of molecular technique used to show that CgOPI1 is essential. 
   
 (A) CgOPI1 was expressed episomally from a single-copy (CEN/ARS) vector 
 carrying a URA3 marker (pCgOPI1).  (B) The chromosomal copy was then 
 disrupted with a Cgopi1∆ disruption cassette by homologous recombination. (C )  
 The resulting Cgopi1∆::NAT1 pCgOPI1 strain was then streaked on 5-FOA 
 medium to select for cells that lost the pCgOPI1 plasmid.  Those which did loose 
 the plasmid could not grow because the chromosomal copy was missing as well 








Figure 5.  The CgOPI1 gene is essential.  
  
 Wild-type (WT) and Cgopi1∆ strains carrying CgOPI1 on a URA3 plasmid 
(pCgOPI1) were grown for 3 days on media +/- 5-FOA at 30˚C.  
 
 
Figure 6.  A CgOPI1-CgINO2 double knockout rescues growth. 
  
 The Cgopi1∆ mutant’s viability defect is dependent on the CgINO2 
transcriptional activator. The wild-type (WT), Cgopi1∆, Cgino2∆, and Cgopi1∆ 




onto synthetic media plates ± 5-FOA.  The WT strain containing the empty vector 
was included as a control.    
 
 
Figure 7.  CgOpi1p is a transcriptional repressor of CgINO1.   
 
 The promoter of the chromosomal copy of CgOPI1 was replaced with the 
doxycycline-repressible tetO::HOP1 promoter.  (A) Expression of CgOPI1, 
CgINO1, and CgACT1 (loading control) were tested by Northern blotting in the 




synthetic medium (contains ~11 µM inositol) lacking doxycycline, washed with 
water, and then resupended in fresh synthetic media containing 0 or 10 µg/ml 
doxycycline and grown for ~6 hours at 30˚C with shaking at which time samples 
were taken for Northern blotting.  (B) Cells were grown on plates containing 0 or 
10µg/ml doxycycline to confirm that loss of CgOPI1 expression decreased 























Figure 8.  Two-step gene deletion method for disrupting CgINO1 in C. glabrata.   
 
 The pRS306-ino1∆ plasmid was cut with NruI and transformed into the BG2 
strain (ura3∆) and selected on SC-ura medium.  The resulting transformant was 
then grown in YPD and plated on 5-FOA medium to select for strains where the 
integrated plasmid had recombined out of the chromosome and was lost.  PCR 
was used to determine which allele (wild-type or disruptant) was left behind.  The 
CgINO1 ORF is shown in gray.  The 500 base-pair 5’ and 3’-non-coding regions 
(NCRs) flanking the ORF are labeled 5 and 3, respectively. The URA3 gene is 



























































Figure 9.  Expression of CgOPI3 and CgCHO1.   
 
 A.  Northern blot measuring gene expression of CgOPI3 and CgCHO1 by wild 
 type and two strains having the CgOPI1 gene fused to the tet system.  This was 
 measured in the presence and absence of 10µg/ml doxycycline.  B. Quantification 
 of northern blot analysis normalized against CgACT1.  Series 1 corresponds to 
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Additional Work in Candida glabrata 
Designing Conditional Mutants in Candida glabrata 
 
There are several vectors that are utilized in yeast to conditionally control gene 
expression.  One such vector contains the promoter of the MtII gene from C. glabrata, 
which is induced in the presence of copper.  When the MtII promoter was fused to the 
lacZ gene of Escherichia coli and transformed into C. glabrata, β-galactosidase activity 
was detected with increasing concentrations of copper (CuSO4) [76]. 
A vector carrying this inducible-conditional promoter (Figure A.5) was used to 
control expression of the CgOPI1 gene, which is essential for the viability of the 
organism.  Although a lack of CuSO4 in the medium led to a lack of detectable 
expression of CgOPI1 from the MtII promoter as measured by Northern blotting (Figure 
A.6A), the conditional mutant remained viable (Figures A.6B and A.6C).  This promoter 
did serve to show that CgOPI1 controls CgINO1 expression, since in the absence of 
detectable CgOPI1 (0 µM CuSO4), the CgINO1 gene was overexpressed (Figure A.6A).  
In as little as 20µM CuSO4, no expression of CgINO1 was detected, while CgOPI1 was 
strongly expressed (Figure A.6A).  
The above analysis was performed using the MTII promoter on an episomal 
plasmid, pEB9 (Figure A.5).  It was hypothesized that the episomal plasmid, although 
centromeric, may be present in multiple copies per cell and may cause enough expression 
of CgOPI1 to explain the strain’s viability even in the absence of extra CuSO4.  CgOPI1 




CgOPI1 was believed to be present based on the fact that a complete CgOPI1 deletion 
mutant is inviable (see chapter 2).  Therefore, the MTII promoter-CgOPI1 construct was 
subcloned into an integrating vector and integrated into the strain at the MTII locus.  This 
resulted in several transformants, some of which failed to grow on plates in the absence 
of CuSO4, and others did grow in the absence of CuSO4 (data not shown).  It was 
hypothesized that the strains that did grow had multiple copies of the plasmid integrated 
and the strains that did not grow had only one copy.  There are three virtually identical 
MTII genes so the multiple integrations seemed possible.  However, Southern blot 
analysis was inclusive, thus we do not know why some strains grew and others did not. 
In order to confirm the essential nature of the gene as well as to obtain a useable 
conditional mutant of CgOPI1, we needed to utilize a vector that would provide a tight 
enough shutoff of the gene to eliminate its viability.  In Candida albicans, the MET3 
promoter can be used to repress gene expression in the presence of cysteine and/or 
methionine [84].  Since C. glabrata has a homologue of this gene, it was hypothesized 
that this could serve as a conditional promoter in this organism.  Again, the viability of a 
strain of C. glabrata containing this vector was not diminished.  When a northern blot 
experiment was performed, the results were ambiguous, leading to the conclusion that the 
C. glabrata homologue of MET3 does not make an efficient conditional promoter (all 
data not shown).   
Sufficient control of CgOPI1 expression was eventually obtained using the 
doxycycline-repressible system, indicating that it is probably the most effective 






 Genes involved in phospholipid biosynthesis are beginning to be studied in 
pathogens in the context of virulence.  In Mycobacterium tuberculosis, a mutant of the 
ino1 gene was attenuated for virulence.  It was quickly cleared from murine macrophages 
in one experiment and unable to cause mortality in mice in another [85].  In Candida 
albicans, the PS synthase-encoding gene, CHO1, has been implicated in virulence, as 
cho1/cho1 mutants are avirulent in mice compared to the wild type.  A knockout of 
both genes responsible for PS decarboxylase, psd1/ psd1 and psd2/psd2 also 
resulted in reduced virulence (Reynolds and Chen, unpublished data).  
 In order to see the phenotype of the Cgcho1 mutant, this gene was disrupted in 
Candida glabrata.  The gene was initially thought to be essential because it was not 
possible to obtain mutants using the two-step gene deletion approach.  Therefore, the 
Cgcho1 mutant was constructed by the same technique used for the Cgopi1 mutant, 
which is depicted in figure 4.  This Cgcho1  mutant carrying the pEB41 plasmid could 
not grow on medium containing 5-FOA unless the media was supplemented with 5mM 
concentrations of ethanolamine or choline.  However, even in 5mM ethanolamine and 
choline, cells grew poorly and unexpectedly could not be subcultured to a new plate 
containing ethanolamine or choline, suggesting that in some way the Cgcho1∆ mutant 
was very sick (data not shown).  In addition, these strains cannot be recovered from the -
80˚C freezer.  Only a strain carrying CgCHO1 on the p41 plasmid could be recovered 
from the -80˚C freezer.  In order to clear this up CgCHO1 was expressed from the MTII 




pEB51.  This was done by transforming the strain carrying pEB41 and Cgopi1::NAT1 
with pEB51, and then selecting on 5-FOA.  This strain could not grow in the absence of 
CuSO4 without exogenous ethanolamine and/or choline (Figure A.7).  However, it grew 
very poorly in the presence of 5mM ethanolamine and choline in the absence of CuSO4, 
and it was very poorly subcultured to a new plate containing 5 mM ethanolamine and 
choline, but not CuSO4.  This strain grew much better when plated on media containing 
CuSO4. (Figure A.8).  
 In S. cerevisiae, respiratory deficiency is correlated with increased levels of 
CHO1 transcript.  PE is a major component of mitochondrial membranes, and it is 
necessary that cells synthesize it in order to grow on nonfermentable carbon sources.   
The cho1 mutant as well as psd1 and psd1psd2 mutants in S. cerevisiae are more 
likely to form petites, or respiratory deficient cells [86].  Respiratory function was also 
affected in cho1, psd1, and psd1psd2 mutants of the non-petite-forming yeast, C. 
albicans (Reynolds and Chen, unpublished data).  Since C. glabrata and S. cerevisiae can 
both form petites, the mitochondrial activity of Cgcho1 mutants was observed using 
fluorescence microscopy with the mitochondria-staining fluorophore, Mito-tracker.  This 
also yielded equivocal results; there was clearly a difference between the wild type and 
the CgCHO1 mutant, but the mutant fluoresced more than expected (Figure A.9).  In an 
attempt to understand these observations, petite mutants of C. glabrata were created, and 
these failed to fluoresce when stained with Mito-tracker (data not shown).  The Cgcho1∆ 




























Figure A. 1.  Relationships among various yeast species.  
  
 This figure is from the website http://cbi.labri.fr/Genolevures/.  It is based on the 
 combined results from multigene concatenation and supertree analyses performed 
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Figure A. 3.  The inositol regulon in S. cerevisiae.  
 
 The inositol regulon in S. cerevisiae controls transcription of phospholipid 
biosynthetic genes like ScINO1 in response to the level of extracellular inositol.  
(A) The ScIno2p-ScIno4p heterodimer activates transcription of ScINO1 and 
other target genes in the absence of extracellular inositol. ScIno2p-ScIno4p  binds 
the upstream activating sequence for inositol regulation (UASINO) present in the 
promoters of genes like ScINO1. (B)  In the presence of extracellular inositol 
ScOpi1p binds to ScIno2p and prevents it from activating transcription of ScINO1 



















CLUSTAL 2.0.10 multiple sequence alignment 
 
 
S.C.Opi1p       ------------------------------------------------------------ 
C.G.Opi1p       ------------------------------------------------------------ 
Y.L.Yas3p       MRKTDPAIEGEEIRGAEVSSSAVIAFCVVITTSHALCPRTCLWCNCTFPPNAPNPNLNPK 60 
C.A.Opi1p       ------------------------------------------------------------ 
                                                                             
 
S.C.Opi1p       --------------------------------------------------MSENQ----- 5 
C.G.Opi1p       --------------------------------------------------MDTRRGWIHN 10 
Y.L.Yas3p       LHKTHERDTANFPSDKGAVSISSQHNHISNTNTTFATSGAQSQYHRLSNNTKTFTRDSPY 120 
C.A.Opi1p       --------------------------------------------------MTAPSISNQQ 10 
                                                                             
 
S.C.Opi1p       ---RLGLSEEEVEAAEVLGVLKQS------------CRQKSQPSEDVS-------QADKM 43 
C.G.Opi1p       YISFSGLSEEDVEAAEALDVLRNSHVDADVEVEEDRSKKRVRDGEDEDGGHVRRRKASVR 70 
Y.L.Yas3p       HSRTPSVDDDGIRQASFLNRVYQSSKSYSPRFRYGAEIVERWASSENTNAATPSASTTNS 180 
C.A.Opi1p       LPPPPYSKTDNLPTSNYQSSLNGSVQGQDQ--QVQAQVQGQAPELVSAAETLTSLTRNGT 68 
                       . : :  :.  . :  *                                     
 
S.C.Opi1p       PASESSTTPLN-------------------------------ILDRVS---NKIISNVVT 69 
C.G.Opi1p       DRSDSRMSQLSNVSNASTEERVVRVNSHEDSQSKRQEE--ESLFDKVCRNSNEILTNMGS 128 
Y.L.Yas3p       NNSNHSNTPVSTTPSSTTMPKALSSKSLDAASIHMASNGAPPLIQKSSLHDFERLKSGID 240 
C.A.Opi1p       PPSDADTVAMDDAQSPVILP-----------PIHPQHQRHPIVSTVSMVARHPIVMNAVK 117 
                  *:     :.                               :           : .    
 
S.C.Opi1p       FYDEINTN-----------------------------KRPLKSIGRLLDDDDDE----HD 96 
C.G.Opi1p       FFEEMNSNVFMEGGSD---------VPEEHPNGYVRPRRDSRSISTTGADADTESQGTQG 179 
Y.L.Yas3p       DIQNSDTNGTQYSVDVGSQGLRMRIQTQGYAPSGNSNRGSPVPPSPALSTSTSSGSTSAA 300 
C.A.Opi1p       YYETSKRNYPSFNYAAG---------------IVESAAIPVVNNIEAKLNTRHQTRQASA 162 
                  :  . *                                             .       
 
S.C.Opi1p       DYD----------YNDDEFFTNKRQKLSRAIAKGKDNLKEYKLNMSIESKKRLVTCLHLL 146 
C.G.Opi1p       SYNGKWDTWSSRSYNDRQYYS-KRKALSEALAKGRYNLREYKLTMSIESKKRLITCLHLL 238 
Y.L.Yas3p       ASRSTSSPVPQQPQTAATAAGGPRPGQPRSAWQEVLISATSLASLSQDSRKRLRYCLHLL 360 
C.A.Opi1p       VSSTDITPTNSNFGDYKIQHDGKNSLQKKRRFSASSQTTNISSYSSIDTKKRLQFCINIL 222 
                                       .    .   .            * :::***  *:::* 
 
S.C.Opi1p       KLANKQLSDKISCLQDLVEKEQVHPLHKQDGNARTTTGAGEDETSSDEDDDDEEFFDASE 206 
C.G.Opi1p       KLANKQLSDKVAYLQDAVEKEQELANGEE---VKKETRALNGEHSGPQNDDDLEFYDASE 295 
Y.L.Yas3p       KLANAHLASTVTKLQGAIAEETAYSLAQS------------IAANHVPHNERQAYLHQPP 408 
C.A.Opi1p       KLANTNISSKVEFLQEKIDETEIAVKEER------------------EKLIAQKSHDSNS 264 
                **** :::..:  **  : :       :                    .       .    
 
S.C.Opi1p       QVNASEQSIVVKMEVVGTVKKVYSLISKFTANSLPEPARSQVRESLLNLPTNWFDSVHST 266 
C.G.Opi1p       SVDQN--SGDLGLEIVGTVKKVYSLISKYTGSSLPEPARSQVRESLLNLPSNWNTSVHNG 353 
Y.L.Yas3p       SAEPALSITALKADVVSTIRKIIKVVSQYAGNSLPEPARSHIRTYILGLPSRWASTTAST 468 
C.A.Opi1p       TNTTEQATQKTKTEIVGTVKKIIHLISNFRPSSLGDTSVTNGLSPVSSNGSQSNQDFELK 324 
                             ::*.*::*:  ::*::  .** :.: ::    : .  :.         
 
S.C.Opi1p       SLPHHASFHYANCEEQKVEQQQQQQQQQQQQQLLQQQLLQQQQQKRNKDGDDSASPSSSV 326 
C.G.Opi1p       FKNNGTGIMTASS---------------------------------STDSLSSYSSILPV 380 
Y.L.Yas3p       NITPTRSPAGSQSPVGSPKECVTPDHQGPPLPTN----TVSSPVPEGPSDEQLSRHRIEV 524 
C.A.Opi1p       NAIRDIIMSLPQS--------------------------------LQQQQQSQQSGPPSN 352 
                          ...                                   .  .         
 
S.C.Opi1p       TANGKVLILAKESLEMVRNVMGVVDSTLGKAEEWVKQKQEVKEMIRERFLQQQQQYRQQ- 385 
C.G.Opi1p       SSNGKYLILAKESLNMVQSVIDVVDSTLGRAEEWVKQKQELKEMIKKKFLEQQEHQKMLG 440 
Y.L.Yas3p       EAGGKVLILANEALDMLGNIISIVDGTLERAEGWCEGINRVKQRVGLGETAPGAAGEPGA 584 
C.A.Opi1p       SQDDVIFKFAKESLVMISKLTQIFTEKLDQVEHWVNGDEEQEQKLQSQSQSPEGLEKQQE 412 
                  ..  : :*:*:* *: .:  :.  .* :.* * :  :. :: :           .    
 
S.C.Opi1p       -----QQKDGNYVKPSQ-----------------DNVDSKD------ 404 
C.G.Opi1p       IGTESLDQNESSVKKEQPTTHISISSITNSTNTLDTVKEEDMHLQKV 487 
Y.L.Yas3p       STEASAEASAEASASAAAAYS-----------AVDTSTDQDVEMGDA 620 
C.A.Opi1p       DEREEENLAAETKRMKLDGSV-------------------------- 433 








CLUSTAL 2.0.10 multiple sequence alignment 
 
 
S.C.Opi1p       MSENQ--------RLGLSEEEVEAAEVLGVLKQS------------CRQKSQPSEDVS-- 38 
C.G.Opi1p       MDTRRGWIHNYISFSGLSEEDVEAAEALDVLRNSHVDADVEVEEDRSKKRVRDGEDEDGG 60 
                *. .:          *****:*****.*.**::*            .::: : .** .   
 
S.C.Opi1p       -----QADKMPASESSTTPLN-----------------------------ILDRVS---N 61 
C.G.Opi1p       HVRRRKASVRDRSDSRMSQLSNVSNASTEERVVRVNSHEDSQSKRQEEESLFDKVCRNSN 120 
                     :*.    *:*  : *.                             ::*:*.   * 
 
S.C.Opi1p       KIISNVVTFYDEINTN--------------------KRPLKSIGRLLDDDDDE----HDD 97 
C.G.Opi1p       EILTNMGSFFEEMNSNVFMEGGSDVPEEHPNGYVRPRRDSRSISTTGADADTESQGTQGS 180 
                :*::*: :*::*:*:*                    :*  :**.    * * *    :.. 
 
S.C.Opi1p       YD----------YNDDEFFTNKRQKLSRAIAKGKDNLKEYKLNMSIESKKRLVTCLHLLK 147 
C.G.Opi1p       YNGKWDTWSSRSYNDRQYYS-KRKALSEALAKGRYNLREYKLTMSIESKKRLITCLHLLK 239 
                *:          *** :::: **: **.*:***: **:****.*********:******* 
 
S.C.Opi1p       LANKQLSDKISCLQDLVEKEQVHPLHKQDGNARTTTGAGEDETSSDEDDDDEEFFDASEQ 207 
C.G.Opi1p       LANKQLSDKVAYLQDAVEKEQELANGEE---VKKETRALNGEHSGPQNDDDLEFYDASES 296 
                *********:: *** *****  .  ::   .:. * * :.* *. ::*** **:****. 
 
S.C.Opi1p       VNASEQSIVVKMEVVGTVKKVYSLISKFTANSLPEPARSQVRESLLNLPTNWFDSVHSTS 267 
C.G.Opi1p       VDQN--SGDLGLEIVGTVKKVYSLISKYTGSSLPEPARSQVRESLLNLPSNWNTSVHNGF 354 
                *: .  *  : :*:*************:*..******************:**  ***.   
 
S.C.Opi1p       LPHHASFHYANCEEQKVEQQQQQQQQQQQQQLLQQQLLQQQQQKRNKDGDDSASPSSSVT 327 
C.G.Opi1p       KNNGTGIMTASS---------------------------------STDSLSSYSSILPVS 381 
                  : :.:  *..                                 ..*. .* *.  .*: 
 
S.C.Opi1p       ANGKVLILAKESLEMVRNVMGVVDSTLGKAEEWVKQKQEVKEMIRERFLQQQQQYRQQ-- 385 
C.G.Opi1p       SNGKYLILAKESLNMVQSVIDVVDSTLGRAEEWVKQKQELKEMIKKKFLEQQEHQKMLGI 441 
                :*** ********:**:.*:.*******:**********:****:::**:**:: :     
 
S.C.Opi1p       ----QQKDGNYVKPSQ-----------------DNVDSKD------ 404 
C.G.Opi1p       GTESLDQNESSVKKEQPTTHISISSITNSTNTLDTVKEEDMHLQKV 487 
                     ::: . ** .*                 *.*..:*       
 
 
Figure A. 4.  ClustalW analysis.  
  
 A.)  ClustalW 2.0.10 multiple sequence alignment comparing Opi1p homologues 
 of S. cerevisiae (S.C.), C. glabrata (C.G.), Y. lipolytica (Y.L.), and C. albicans 
 (C.A.).  Asterisk represents conservation among all four species.  Various 
 domains represented by different colors. Blue:  Opi1-Sin3 interaction domain.  
 Gold:  PA-binding domain.  Red:  Leucine zipper.  Green:  FFAT.  Purple:  
 Polyglutamine Tract.  Orange:  Activator Interaction Domain. 





Figure A. 5.  Plasmid initially used to create MtII-CgOPI1 fusion.   
 
 pEB9 is an episomal plasmid that was transformed into a strain containing the 
 CgOPI1 gene on another plasmid with a URA3 marker.  The chromosomal 
 CgOPI1 was replaced with a nourseothricin-resistance cassette.  The plasmids 
 used for integrating MtII-CgOPI1 and MtII-CgCHO1 fusions (pEB37 and pEB51, 








































































Figure A. 6.  CgOPI1 with MtII promoter integrated into the chromosome. 
   
 A.)  Northern Blot analysis of the expression of CgOPI1 and CgINO1 in the 
 presence of varying concentrations of CuSO4.  B.)  Strains with CgOPI1-MtII 
 construct grown in SC liquid media in the absence (top) and presence (bottom) of 
 50 mM CuSO4.  Strains are in order from left to right Cg1 (WT), EBCg049-3,  
 EBCg049-8, EBCg049-10, EBCg049-11, EBCg049-12.  C.) CgOPI1-MtII 
 constructs grown on SC solid media in the absence (left) and presence (right) of 
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Figure A. 7. CgCHO1 mutant is an ethanolamine and choline auxotroph.  
 
  Plated on SC media without CuSO4.  EBCg045 B and C are two isolates that 
 carry integrating plasmid, pEB51, which has CgCHO1 fused to the MtII 
 promoter.  A.) 0 µm ethanolamine and 0µm choline.  B.) 5µm ethanolamine and 
 5µm choline. 
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Figure A. 8.  MtII promoter controls expression of CgCHO1 
.   
 C. glabrata strain containing integrating plasmid pEB51 carrying the MtII 
 promoter fused to CgCHO1 along with CgCHO1 on an episomal plasmid, pEB41, 
 containing the URA3 gene. Plated on 5-FOA.  A.) 0µm CuSO4.  B.) 50µm CuSO4.   
EBCg044 C EBCg044 B 
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Figure A. 9.  Fluorescence microscopy of cells stained with Mito-tracker.  
 
















Table 4.  Plasmids used for data in Chapter III. 
Plasmids Type Description 
pEB9 episomal MtII-CgOPI1, HIS3, 
CgCEN/ARS, AmpR 
pEB37 integrating—Sma1 MtII-CgOPI1, HIS3, AmpR 
pEB41 Episomal CgCEN/ARS, AmpR, URA3, 
CgCHO1 ORF + 5’,3’ NCRs 





Table 5.  Strains used for data in Chapter III. 
Strain Genotype 
EBCg044 ura3::Tn903 NeoR, his3, pEB41, pEB51, 
CgCHO1::NatR 
EBCg045 Ura3::Tn903 NeoR, his3, CgCHO1::NatR, pEB51 
EBCG035 Ura3::Tn903 NeoR, his3, pEB41, CgCHO1::NatR 
EBCg049 Ura3::Tn903 NeoR, his3, pEB37, CgOPI1::NatR, 
pCgOPI1—URA3 
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